BEF, Author at The Boomer Esiason Foundation

March 19, 2019

Vertex Pharmaceuticals Inc. today announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) modulators for the treatment of cystic fibrosis (CF). The trial is designed to evaluate the...

PTC Therapeutics Awarded $1.6 Million FDA Grant to Support Ongoing Phase 3 Study of Ataluren

by BEF

CF News, Therapies

March 19, 2019

PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF). The...

New CF Drugs Bring Hope; More Survive Into Adulthood, But They Face New Challenges

by BEF

CF News, Therapies

March 19, 2019

Emily Schaller likes to travel as part of the cystic-fibrosis advocacy she does, but the daily regimen she uses to manage her disease weighs her down. “You have to bring three extra bags with meds and the vest,” she said. Schaller, 28, takes five or six pills...

Eurand Reports Further Positive Data from Pancreatic Insufficiency Drug Study

by BEF

CF News, Therapies

March 19, 2019

Eurand Pharmaceuticals, a subsidiary of specialty pharmaceutical company Eurand, has announced additional data from a post-hoc analysis of a Phase III clinical trial with Zenpep delayed-release capsules, an FDA-approved pancreatic enzyme product, or PEP, for the treatment of exocrine pancreatic insufficiency in patients with cystic...

Cincinnati Children’s Cited in US News Report As a ‘Best’ Hospital for CF Kids

by BEF

CF News, Therapies

March 19, 2019

A 'Best' Hospital for Cystic Fibrosis Kids Unhappy with its so-so record, Cincinnati Children's used tools of health reform to turn itself around Waiting to be ushered into an outpatient examination room at Cincinnati Children's Hospital Medical Center, Alicia Lang doesn't chatter on like most 18-year-old girls....

Limit Antibiotics for CF Exacerbations to 10 Days, Registry Study Says

by BEF

CF News, Therapies

March 19, 2019

Less may be more when it comes to treatment of cystic fibrosis exacerbations. A retrospective analysis of more than 1,500 patients suggests nothing is gained by extending intravenous (IV) antibiotic treatment beyond 8 to 10 days, or by giving antibiotics in the hospital. Furthermore, therapy doesn't necessarily...

Lilly to Acquire Alnara; Company’s Liprotamase Currently Under FDA Review

by BEF

CF News, Therapies

March 19, 2019

Eli Lilly and Company and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine...

FDA Extends Availability of Pancreatic Enzyme Therapy Pancrease Until Mid-July

by BEF

CF News, Therapies

March 19, 2019

The CF Foundation has learned that the U.S. Food and Drug Administration will allow wholesalers to distribute the pancreatic enzyme product Pancrease® MT to pharmacies until July 12, 2010. At that time, an updated formula called PancreazeTM will become available and will replace Pancrease. Several days...

Pancreatic Enzyme Therapy Pancrease to Have Limited Availability, CFF Says

by BEF

CF News, Therapies

March 19, 2019

The Cystic Fibrosis Foundation has learned that the pancreatic enzyme product Pancrease will be available in limited supply at pharmacies around the country until an updated formula called Pancreaze™ is made available this summer. Pancreaze is manufactured by Johnson and Johnson Pharmaceutical Research and Development. The CF...

Data Suggest Denufosol May Hold Promise as an Early Intervention Treatment for CF

by BEF

CF News, Therapies

March 19, 2019

Inspire Pharmaceuticals, Inc. announced today that Inspire scientists and collaborators will present data on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation at the American Thoracic Society (ATS) 2010 International Conference May 14 - 19, 2010 in New Orleans, LA....

Author: BEF

Vertex Pharmaceuticals Clinical Trial to Evaluate Combo of VX-770 and VX-809 Targeting CFTR Protein

PTC Therapeutics Awarded $1.6 Million FDA Grant to Support Ongoing Phase 3 Study of Ataluren

New CF Drugs Bring Hope; More Survive Into Adulthood, But They Face New Challenges

Eurand Reports Further Positive Data from Pancreatic Insufficiency Drug Study

Cincinnati Children’s Cited in US News Report As a ‘Best’ Hospital for CF Kids

Limit Antibiotics for CF Exacerbations to 10 Days, Registry Study Says

Lilly to Acquire Alnara; Company’s Liprotamase Currently Under FDA Review

FDA Extends Availability of Pancreatic Enzyme Therapy Pancrease Until Mid-July

Pancreatic Enzyme Therapy Pancrease to Have Limited Availability, CFF Says

Data Suggest Denufosol May Hold Promise as an Early Intervention Treatment for CF

Never miss an update. Subscribe to our emails!